Insulin-like growth factors and neoplasia.
Pollak
Michael N
MN
Department of Oncology, McGill University and Lady Davis Research Institute, 3999 Rue Côte Sainte Catherine, Montreal, Quebec H3T 1E2, Canada. michael.pollack@mcgill.ca
Schernhammer
Eva S
ES
Hankinson
Susan E
SE
D000375:Aging / Q000502:physiology; D000818:Animals; D017209:Apoptosis; D002455:Cell Division; D002471:Cell Transformation, Neoplastic; D002986:Clinical Trials as Topic; D004198:Disease Susceptibility; D004734:Energy Metabolism; D006706:Homeostasis; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D018969:Insulin-Like Growth Factor Binding Proteins / Q000502:physiology; D008019:Life Style; D008136:Longevity / Q000502:physiology; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000378:metabolism*; D017451:Receptors, Somatomedin / Q000037:antagonists & inhibitors / Q000502:physiology; D012307:Risk Factors; D015398:Signal Transduction; D013002:Somatomedins / Q000037:antagonists & inhibitors / Q000502:physiology*; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
D018969:Insulin-Like Growth Factor Binding Proteins; D017451:Receptors, Somatomedin; D013002:Somatomedins; D013004:Somatostatin